Web Results


Bristol is trying to build off of Eliquis momentum, signing a cardiovascular gene therapy deal with uniQure; Celgene capitalized on build-to-buy model and exercised option for Quanticel. Biopharma financing was down by almost $3 billion, while device fundraising was slightly up. BioPharmaceutical Medical Device.


Cipher Pharmaceuticals is a growing specialty company with a focus on dermatology. Our goal is to develop and acquire best-in-class skin care solutions.


Apr 13, 2015 ... Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced Cipher Pharmaceuticals' (NASDAQ: CPHR) acquisition of INNOCUTIS. Holdings LLC, the licensee of Sitavig® in the USA. Cipher Pharmaceuticals (“Cipher”) is a ...


Also Known As: Innocutis Holdings LLC. Website: innocutis.com. Twitter: View on Twitter. Phone Number: 843-965-8333. INNOCUTIS is a pharmaceutical and medical device company specializing in the development and commercialization of therapies and devices focused on medical treatment of dermatological ...


Cipher Pharmaceuticals US LLC company research & investing information. Find executives and the latest company news.


Apr 13, 2015 ... MISSISSAUGA, ON, April 13, 2015 /CNW/ - Cipher Pharmaceuticals Inc. ( NASDAQ: CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that it has acquired INNOCUTIS Holdings LLC ("INNOCUTIS"), a privately held specialty dermatology company, for US$45.5 million in cash. All financial ...


Sep 26, 2011 ... Charleston-based dermatology drug and device firm Innocutis Holdings LLC announced Monday that it has received a $6.5 million investment from a Florida venture capital fund.


Current. EPI Health ,; Cipher Pharmaceuticals Inc. Previous. Innocutis Holdings, LLC,; Innocutis Medical, LLC,; Medicis. Education. University of South Carolina- Columbia. Websites. Company Website ...


Learn about Nuvail (by Innocutis Holdings LLC), drug uses, dosage, side effects, indications, description.